Tumescent-assisted interstitial (intradermal/subcutaneous) 1470 nm diode laser treatment for primary axillary hyperhidrosis: a prospective single-center series of 23 cases with 12-month follow-up
Laser Therapy · 01.04.2026 · 33 (1)
DOI: 10.4081/ltj.2026.429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laser Therapy, online erschienen am 01.04.2026. Verfasst von Luigi Mazzi. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Primary axillary hyperhidrosis (AH) is a chronic condition that significantly impacts quality of life. The 1470 nm wavelength, characterized by high hydro-absorption, offers the potential for more confined photo-thermocoagulation of the glandular compartment when energy is delivered interstitially under tumescent anesthesia. We conducted an uncontrolled single-center prospective series on 23 adults (16 men, 7 women; aged 21-53 years) treated using a 1470 nm diode laser (LASEmaR 1500®, Eufoton®, Trieste, Italy) connected to a 400 μm optical fiber inserted into a hollow cannula with an open tip and blunt end through 2-3 access points per axilla. Follow-up was carried out at 6 and 12 months. Outcomes included Hyperhidrosis Disease Severity Scale (HDSS; primary endpoint), gravimetry (mg/5 min), local humidity (%), Dermatology Life Quality Index (DLQI), Global Aesthetic Improvement Scale (GAIS), and safety. The protocol allowed selective retreatment at 6 months in patients with clinically relevant residual activity/high functional demands. All patients achieved HDSS ≤2 at both 6 and 12 months. Mean gravimetry decreased from 128.8±27.7 to 38.4±10.8 and 32.0±9.4 mg/5 min; humidity from 75.3±5.8% to 45.7±3.3% and 43.4±3.6%. DLQI fell from 15.9±4.4 to 5.0±1.1 and 4.3±1.1. At 12 months, overall assessment was excellent in 82.6% (19/23), good in 8.7% (2/23), and fair in 8.7% (2/23). Adverse events were mild and transient, with no infections or burns. Of the 23 participants, 16 underwent a single treatment session, while 7 received a retreatment at 6 months. In this prospective case series, interstitial 1470 nm laser with tumescent assistance was associated with clinically relevant improvement up to 12 months and a favorable tolerability profile. Given the uncontrolled observational design and selective retreatment in a subset, these findings should be considered hypothesis-generating and warrant confirmation in comparative studies.
Zitieren
APA
Mazzi, L. (2026). Tumescent-assisted interstitial (intradermal/subcutaneous) 1470 nm diode laser treatment for primary axillary hyperhidrosis: a prospective single-center series of 23 cases with 12-month follow-up. Laser Therapy, 33(1). https://doi.org/10.4081/ltj.2026.429
Vancouver
Mazzi L. Tumescent-assisted interstitial (intradermal/subcutaneous) 1470 nm diode laser treatment for primary axillary hyperhidrosis: a prospective single-center series of 23 cases with 12-month follow-up. Laser Therapy. 2026;33(1). doi:10.4081/ltj.2026.429
BibTeX
@article{Mazzi2026,
author = {Mazzi, Luigi},
title = {Tumescent-assisted interstitial (intradermal/subcutaneous) 1470 nm diode laser treatment for primary axillary hyperhidrosis: a prospective single-center series of 23 cases with 12-month follow-up},
journal = {Laser Therapy},
year = {2026},
volume = {33},
number = {1},
doi = {10.4081/ltj.2026.429}
}
EUVIMED